Background: This retrospective study evaluated the short-term effects of the SGLT2 inhibitor Dapagliflozin on laboratory markers in patients with type 2 diabetes mellitus (T2DM) over six months. This evidence concerns the gene SLC5A2 and diabetes mellitus.